rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BIOA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      BioAge Labs to Present at Upcoming Investor Conferences

      EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ('BioAge', 'the Company'), a clinical-stage biopharmaceut...

      Nov 11Business InsiderBIOA
      BioAge Labs, Inc. (BIOA) Reports Q3 Loss, Misses Revenue Estimates
      Nov 5Yahoo FinanceBIOA
      BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

      First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027 QUELL-CV, a Phase 2 dose-ranging trial of BGE-102 in adults with obesity and elevated baseline inflammation, completed enrollment; topline data anticipated in the fourth quarter of 2026 APJ agonist program, an exercise-mimetic approach to obesity, on track for IND submission by year-end 2026 EMERYVILLE,

      Nov 5Yahoo FinanceBIOA
      Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline

      BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Oct 29Yahoo FinanceBIOA
      BioAge Labs, Deep Origin Collaborate on AI-Driven Drug Discovery
      Oct 14Yahoo FinanceBIOA
      BioAge Labs, Inc. (BIOA) Has a New Rating from UBS

      Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

      Oct 12The Globe and MailBIOA
      BioAge Labs' Lead Drug Faces Uncertain Path as Data Looms, UBS Says
      Oct 12Yahoo FinanceBIOA
      UBS initiates BioAge Labs stock coverage at neutral on DME focus
      Oct 12Investing.comBIOA
      BioAge Labs to Present at Upcoming Investor Conferences

      EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ('BioAge', 'the Company'), a clinical-stage biotechnolog...

      Sep 25Business InsiderBIOA
      Analysts Offer Insights on NA Companies: Fair Isaac (FICO), Freeport-McMoRan (FCX) and BioAge Labs, Inc. (BIOA)

      Detailed price information for Freeport-Mcmoran Inc (FCX-N) from The Globe and Mail including charting and trades.

      Sep 15The Globe and MailBIOAFICO
      Analysts’ Top NA Picks: BioAge Labs, Inc. (BIOA), OS Therapies Incorporated (OSTX)

      Detailed price information for Evommune Inc (EVMN-N) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailBIOAOSTX
      BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

      Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapyPrimary...

      Sep 8Business InsiderBIOA
      BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off (BIOA)

      BioAge's diversified pipeline includes ophthalmology and apelin-APJ pathway programs, and partnerships with Novartis and Eli Lilly. See why BIOA stock is a buy.

      Sep 5Seeking AlphaBIOA
      BioAge Labs to Present at Upcoming Investor Conferences

      EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ('BioAge', 'the Company'), a clinical-stage biotechnolog...

      Sep 2Business InsiderBIOA

      This is the newest page. Registered accounts read further back.